Fidelity Investments
AURA icon

Fidelity Investments’s Aura Biosciences AURA Stock Holding History

Fidelity Investments’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.81M Buy
255,331
+252,437
+8,723% +$1.81M ﹤0.01% 2789
2026
Q1 		$19.4K Sell
2,894
-5,244
-64% -$30.1K ﹤0.01% 4529
2025
Q4 		$44.4K Buy
8,138
+4,671
+135% +$27.7K ﹤0.01% 4170
2025
Q3 		$21.4K Buy
3,467
+1,925
+125% +$12.6K ﹤0.01% 4327
2025
Q2 		$9.65K Sell
1,542
-28,102
-95% -$164K ﹤0.01% 4538
2025
Q1 		$174K Sell
29,644
-1,901
-6% -$14.4K ﹤0.01% 3304
2024
Q4 		$259K Sell
31,545
-69,672
-69% -$656K ﹤0.01% 3164
2024
Q3 		$902K Sell
101,217
-129,234
-56% -$1.11M ﹤0.01% 2631
2024
Q2 		$1.74M Sell
230,451
-64,203
-22% -$470K ﹤0.01% 2385
2024
Q1 		$2.31M Sell
294,654
-62,381
-17% -$517K ﹤0.01% 2296
2023
Q4 		$3.16M Sell
357,035
-1,526
-0.4% -$12.9K ﹤0.01% 2199
2023
Q3 		$3.22M Sell
358,561
-75
-0% -$807 ﹤0.01% 2162
2023
Q2 		$4.43M Buy
358,636
+1,789
+0.5% +$19.1K ﹤0.01% 2101
2023
Q1 		$3.31M Sell
356,847
-371,550
-51% -$3.86M ﹤0.01% 2230
2022
Q4 		$7.65M Buy
728,397
+124,636
+21% +$1.59M ﹤0.01% 1996
2022
Q3 		$10.9M Buy
603,761
+290
+0% +$4.39K ﹤0.01% 1859
2022
Q2 		$8.55M Buy
603,471
+109,362
+22% +$1.81M ﹤0.01% 2033
2022
Q1 		$10.9M Buy
494,109
+22,809
+5% +$435K ﹤0.01% 2090
2021
Q4 		$8M Buy
+471,300
New +$8.42M ﹤0.01% 2202

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments's AURA Position: Q2 2026 in Review

Fidelity Investments increased its Aura Biosciences (AURA) stake by 8,723% in Q2 2026, buying an estimated $1.81M and bringing the position to 255,331 shares worth $1.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2789.

Fidelity Investments first reported a position in AURA in Q4 2021 and has held it in 19 quarters since. The position peaked at $10.9M in Q3 2022. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Fidelity Investments held 255,331 shares of Aura Biosciences worth $1.81M as of Q2 2026.
  • Fidelity Investments bought 252,437 Aura Biosciences shares in Q2 2026, an estimated $1.81M.
  • Aura Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2789 holding.
  • Fidelity Investments first reported a position in Aura Biosciences in Q4 2021 and has held it in 19 quarters since.
  • Fidelity Investments's Aura Biosciences position peaked at $10.9M in Q3 2022.
  • 146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.